Cytiva expanded its collaboration with Culture Biosciences, which specializes in cloud-connected bioreactor technology, to include both hardware commercialization and technology development.
Building on an existing agreement to offer a Cytiva 250mL consumable featuring a scaled-down version of its Xcellerex X-Platform technology for use with Culture’s Stratyx 250 system, the expanded relationship will now include global commercialization by Cytiva of Culture’s Stratyx 250 hardware and joint development of additional bioreactor formats.
“By aligning our innovative bioreactor technology with Cytiva’s global reach and leadership in bioprocessing, we are accelerating the future of digital bioprocessing,” says Chris Williams, CEO, Culture Biosciences.
Cytiva will serve as the exclusive global distributor of Culture’s Stratyx 250 bioreactor platform and associated consumables. Cytiva’s global infrastructure and customer reach will help ensure broad access to this next-generation, small-scale bioprocessing technology, maintains Jon Van Pelt, vice president and general manager, single use technologies, Cytiva, says. The companies will collaborate to expand the Stratyx product line. This expanded portfolio will feature consumables built with Cytiva’s Xcellerex X-Platform technology, enabling seamless scale-up from 250 mL to 2,000 liters, adds Van Pelt.
“Expanding our collaboration with Culture Biosciences will help us deliver smarter, scalable, and connected biomanufacturing systems for our customers,” he continues.
The post Cytiva Expands Collaboration with Culture Biosciences appeared first on GEN – Genetic Engineering and Biotechnology News.
